NCT06481098View on ClinicalTrials.gov

A Phase 1 Study to Assess HM15275 in Healthy and Obese Subjects.

PHASE1CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

May 28, 2024

Primary Completion Date

May 2, 2025

Study Completion Date

May 2, 2025

Conditions
Obesity
Interventions
DRUG

HM15275

HM15275 is a sterile solution for subcutaneous injection, supplied pre-filled syringes.

DRUG

Placebo of HM15275

A sterile, matching solution supplied in pre-filled syringes.

Trial Locations (1)

91911

ProSciento, Inc., Chula Vista

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY